Illumina Inc ILMN:NASDAQ

Last Price$303.01NASDAQ Closing Price as of 3:59PM ET 9/18/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+4.74(1.59%)
Bid (Size)$303.00 (1)
Ask (Size)$305.00 (1)
Day Low / High$297.78 - 303.13
Volume957.3 K

View Biotechnology IndustryPeer Comparison as of 09/18/2019


Illumina Inc ( NASDAQ )

Price: $303.01
Change: +4.74 (1.59%)
Volume: 957.3 K
3:59PM ET 9/18/2019

Biogen Inc ( NASDAQ )

Price: $235.17
Change: -3.53 (1.48%)
Volume: 1.6 M
3:59PM ET 9/18/2019

Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $174.52
Change: -1.48 (0.84%)
Volume: 1.2 M
3:59PM ET 9/18/2019

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $285.06
Change: -3.06 (1.06%)
Volume: 562.3 K
4:00PM ET 9/18/2019

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $102.98
Change: -4.85 (4.50%)
Volume: 3.5 M
3:59PM ET 9/18/2019

Read more news Recent News

US Stocks Modestly Higher Amid Positive Economic Data, Strong Energy Gains
11:46AM ET 9/11/2019 MT Newswires

US equity benchmarks were modestly higher on Wednesday morning, helped by strong gains in the energy and communication services sectors and a raft of...

Qiagen, Columbia University File Patent Infringement Lawsuit Against Illumina
2:43PM ET 9/10/2019 MT Newswires

Qiagen (QGEN), a Netherlands-based diagnostics and research company, together with Columbia University, on Tuesday filed a patent infringement lawsuit...

Insider Trends: Illumina Insider Continues 90-Day Selling Trend
4:31PM ET 9/05/2019 MT Newswires

Charles Dadswell, SVP & General Counsel, reported a sale of 1,220 shares in Illumina (ILMN) on Sep 03, 2019, for $341,454. Dadswell, after the...

Insider Trends: Insider Prolongs 90-Day Selling Trend at Illumina
4:35PM ET 8/29/2019 MT Newswires

Jay T Flatley, Director, sold 3,300 shares of Illumina (ILMN) on Aug 28, 2019, for $935,253. Subsequent to the Form 4 filing with the SEC, Flatley...

Company Profile

Business DescriptionIllumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA. View company web site for more details
Address5200 Illumina Way
San Diego, California 92122
Number of Employees7,300
Recent SEC Filing09/05/20194
President, Chief Executive Officer & DirectorFrancis A. deSouza
Senior Vice President-Global Quality & OperationsRobert P. Ragusa
Chief Financial Officer & Senior Vice PresidentSam A. Samad
Chief Technology Officer & Senior Vice PresidentMostafa Ronaghi

Company Highlights

Price Open$298.69
Previous Close$298.27
52 Week Range$263.30 - 380.76
Market Capitalization$44.5 B
Shares Outstanding147.0 M
SectorHealth Technology
Next Earnings Announcement10/22/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings47.34
Earnings per Share$5.72
Beta vs. S&P 500N/A
Revenue$3.3 B
Net Profit Margin27.56%
Return on Equity24.09%

Analyst Ratings as of 09/06/2019

Consensus RecommendationConsensus Icon
Powered by Factset